Register now for "Collaborating for a Cure," the SRF Patient Forum, on June 3rd! 📋 You're invited to a FREE virtual forum for people living with #scleroderma and those who care...
Read More
Here at the Scleroderma Research Foundation, research is at the center of all we do to find a cure—and that's only possible because of the dedicated support of our community....
Read More
Earlier this month, the Scleroderma Research Foundation hosted an international group of investigators to learn more about CONQUEST, our groundbreaking platform clinical trial, at the Systemic World Congress Meeting in...
Read More
Research is at the center of all we do here at the SRF to find a cure for scleroderma. This is why, in 2018, we launched CONQUER (COllaborative, National QUality...
Read More
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
• Sanofi is inaugural partner • Initial focus on Interstitial Lung Disease Secondary to Scleroderma • SRF will submit and hold the IND as the trial Sponsor SAN FRANCISCO, August...
Read More
Today, the Scleroderma Research Foundation announces the launch of CONQUEST, a highly innovative platform clinical trial designed to rapidly advance promising treatments for scleroderma. Industry partner, Sanofi, will contribute the first experimental...
Read More
Dear Friends, Thank you for your dedication to the mission of the Scleroderma Research Foundation (SRF) where research is at the center of everything we do. Below you’ll find an update on...
Read More
Meet the Scleroderma Research Foundation’s newest staff member. Please join us in welcoming our new Development Database Manager, Ruben Cordoba. Ruben brings a strong analytical mindset and technical expertise to…
Amazon has announced that they are discontinuing AmazonSmile on February 20, 2023. To everyone who prioritized the SRF while you shopped, thank you. You’ve helped us accelerate the pace of…
